<p>This poster was presented by Dr. Silverberg and colleagues at the 2020 American Academy of Dermatology virtual annual meeting.</p>
<p>This overview is provided by Dr. Alan Fleischer.</p>

Dupilumab Treatment for up to Three Years Demonstrates Sustained Efficacy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Liberty AD Adult Open Label Extension

Welcome to this activity focusing on new research related to atopic dermatitis presented as posters at the 2020 virtual annual meetings of the American Academy of Dermatology and the American Academy of Allergy, Asthma, and Immunology. The posters focus on new data related to the use of advanced therapies for atopic dermatitis. Beyond discussing the methods and results of each poster, the faculty, Drs. Steven Feldman and Alan Fleischer, Jr., share their views on the implication of the trial results on clinical practice.

Anchor (from Spotify)

Research Developments in Atopic Dermatitis

Peak Pruritus Numeric Rating Scale, the PPNRS, Response with Abrocitinib in Patients with Moderate to Severe Atopic Dermatitis: Results from a Randomized Phase 3 Clinical Trial